- Research article
- Open Access
- Open Peer Review
Dietary restriction during the treatment of cancer: results of a systematic scoping review
BMC Cancer volume 19, Article number: 811 (2019)
Diets that restrict energy or macronutrient intake (e.g. fasting/ketogenic diets (KDs)) may selectively protect non-tumour cells during cancer treatment. Previous reviews have focused on a subset of dietary restrictions (DR) or have not performed systematic searches. We conducted a systematic scoping review of DR at the time of cancer treatment.
MEDLINE, Embase, CINAHL, AMED and Web of Science databases were searched for studies of adults undergoing DR alongside treatment for cancer. Search results were screened against inclusion/exclusion criteria. Data from included studies were extracted by two independent reviewers. Results were summarised narratively.
Twenty-three independent studies (34 articles), with small sample sizes, met the inclusion criteria. Four categories were identified: KDs (10 studies), fasting (4 studies), protein restriction (5 studies) and combined interventions (4 studies). Diets were tolerated well, however adherence was variable, particularly for KDs. Biomarker analysis in KDs and fasting resulted in the expected increase in ketones or reduction in insulin-like growth factors, respectively, however they did not reduce glucose.
Future research with adequately powered studies is required to test the effects of each DR intervention on treatment toxicities and outcomes. Further research into improving adherence to DR may improve the feasibility of larger trials.
Pre-clinical studies in model organisms have identified the potential protective effect of restricting overall energy intake or specific macronutrient intake on resistance to stress in these models. This has led to a growing interest in the use of restrictive diets to potentially attenuate the cytotoxic effects of cancer treatments such as chemotherapy and radiotherapy . Examples of diets of interest include fasting, which restricts overall energy intake, and ketogenic diets, which restrict energy intake from carbohydrate sources. Collectively these diets can be referred to as dietary restriction (DR) .
Cellular metabolism in cancer
When nutrients are not available, non-tumour cells are able to alter their cell signalling processes, withdrawing energy from growth/reproduction in order to conserve their energy for maintenance/repair. This leads to increased cellular protection . This process is partially mediated by a reduction in growth factors, specifically insulin-like growth factor-1 (IGF-1) . A reduction in IGF-1 reduces the activation of the Ras/MAPK and P13K/Akt pathways that promote expression of genes involved in proliferation, growth, survival and increased protein synthesis via mTOR.
Conversely, cancer is a disease associated with dysregulated metabolism . One of the hallmarks of cancer is the ability of tumour cells to continue to grow in the absence of growth factors, such as when nutrients are scarce . Mutated tumour cells evade these signals due to gain-of-function mutations in oncogenes (Ras, Akt, mTOR), which results in proliferation pathways continually being active, even in the absence of growth signals . Therefore, tumour cells do not respond to nutrient deprivation in the same way as healthy cells and continue to proliferate, even when nutrients are scarce.
Furthermore, tumour cells are known to rely on glycolysis for energy production, the phenomenon of fermenting glucose to form lactic acid, rather than mitochondrial oxidative phosphorylation, even in the presence of oxygen . This process has been coined the Warburg effect and can be thought of as a trade-off of “catabolic efficiency for anabolic utility” as the energy produced by the fermentation of glucose can be used for biosynthesis required for daughter cells during proliferation [8, 9]. This metabolic dysregulation is seen in nearly all tumour cells and may put these cells under increased pressure when glucose availability is low, requiring cells to switch from glucose metabolism to ketone metabolism and fatty acid oxidation .
This difference in reaction to nutrient scarcity between healthy and tumour cells is termed differential stress resistance and may render tumour cells more susceptible to the effects of chemotherapy while at the same time helping to protect healthy cells against the toxic effect of chemotherapy . It is thought that through mechanisms such as decreased growth signalling for healthy cells and the lack of metabolic adaptability found in tumour cells, DR may lead to the increased vulnerability of tumour cells to treatment. Therapeutic regimes that take advantage of this differential stress resistance are therefore a potential tool in the treatment of cancer.
Dietary restriction (DR)
Methods of DR such as fasting, carbohydrate restriction or protein restriction are dietary strategies which aim to exploit this difference in energy metabolism between healthy and tumour cells .
Chronic energy restriction and fasting lead to reduced blood glucose and IGF-1 and increased ketones . However, chronic energy restriction may not be suitable for patients undergoing treatment with chemotherapy or radiotherapy due to the increased risk of cachexia and sarcopenia [3, 10]. Short term fasting (for example complete energy restriction lasting up to 4 days) at the time of chemotherapy has therefore been suggested as a potential therapy without the risks of chronic energy restriction . More recently, a fasting mimicking diet has been created that mimics the physiological effect of fasting without having to reduce daily energy intake below 725 kcal. This diet aims to overcome some of the difficulties of short term, water only fasting, such as issues with adherence, adverse effects and malnourishment .
As well as energy restriction, the composition of restricted diets may also be of importance. Ketogenic diets (KDs) are high in fat with restricted carbohydrate intake. For example, the 4:1 KD comprises fats in a 4:1 ratio to carbohydrates, whilst also limiting protein intake, so that approximately 90% of calories are derived from fat . KDs simulate many of the physiological responses of energy restriction such as a reduction in blood glucose and IGF-1 coupled with an increase in ketones [10, 11].
Protein restriction is another form of macronutrient restriction of interest. Epidemiological research has found that people following energy unrestricted plant-based diets, with reduced protein, have lower IGF-1 concentrations than those on long-term severe calorie restriction with adequate protein. This suggests that protein restriction may be another therapeutic strategy . Protein restricted diets aim to reduce intake of total protein or of specific essential amino acids. Methionine is of particular interest, as an amino acid that has been recognised to have an important role in cellular metabolism. It is required for protein synthesis and DNA methylation required in cell growth/proliferation .
Reviews on DR that have been published to date have focused on subsets of DR studies and not all have been systematic in their search criteria.
Previous systematic reviews have been conducted in fasting  and KDs . The review of fasting included studies on the effects of chemotherapy and studies on tumour progression, without chemotherapy. Authors concluded that fasting was seen to reduce chemotherapy side effects and suppress tumour progression. They also concluded that a 24 h fast may not be long enough for the protective effects of fasting to apply, due to two human studies which found less toxicities in 72 h fasts when compared to 24 h fasts [17, 18]. The review of KDs was not specifically in populations receiving active treatment for cancer . Authors report inconclusive evidence for changes in nutritional status and adverse events as well as low adherence to KDs. No systematic reviews have been conducted on other forms of DR during treatment for cancer e.g. fasting mimicking diets or protein restriction.
In addition to the systematic reviews, two perspective reviews describing the rationale behind fasting and fasting mimetics at the time of chemotherapy have also been identified [3, 10]. These reviews describe how the findings in simple organism and animal models provide a rationale behind the use of some forms of DR and provide an overview of previous  and ongoing  DR trials. These reviews, however, do not describe a systematic search of the literature, and additional studies on DR in humans, not included in these reviews, have been identified.
Unlike a systematic review and meta-analysis, scoping reviews have a broader scope and provide a description of current evidence, regardless of quality . This allows research on emerging fields, such as DR during treatment for cancer, which may not yet have results from many randomised controlled trials, to be presented and summarised in a systematic way. As such, a comprehensive systematic scoping review to identify studies in humans looking at the different types of DR at the time of cancer treatment is warranted. This review will provide a clear overview of research in this area to date and identify future research priorities.
Aims and objectives
The aim of this scoping review is to summarise the research on the effects of dietary restriction on cancer treatment induced toxicities and outcomes in adult patients undergoing treatment for any malignancy.
The primary objective is to identify and characterise the research that has been conducted to date on dietary restriction as an adjuvant therapy in the treatment of cancer in adults with cancer. The secondary objective is to explore the acceptability of dietary restrictions in the samples identified through the search.
A scoping review protocol was developed and made publicly available prior to commencement of this review .
Inclusion criteria were defined in terms of Population, Concept and Context .
Adult participants undergoing some form of dietary restriction as an adjuvant treatment for any type of cancer.
Any form of dietary restriction studies which assessed:
The safety or feasibility of the interventions and/or
The effect of the interventions on outcomes such as chemotherapy toxicities, clinical outcomes or cancer biomarkers. Examples of the dietary restriction forms of interest are short/long term fasts, intermittent fasts, fasting mimicking diets, ketogenic diets or protein restriction diets.
Any cancer care setting. The intervention could be delivered in combination with any standard treatment for cancer e.g. chemotherapy, radiotherapy or immunotherapy.
Studies of animal models or model organisms were not included in this review. Although not specified in our original protocol, as we were interested in diets that initiate the metabolic changes associated with differential stress resistance and not diets that altered macronutrient composition without aiming to induce such changes, low fat diets which solely aimed to reduce weight in cancer populations were also excluded.
Types of sources
All forms of quantitative and qualitative primary research were included, as were systematic reviews and meta-analyses. As dietary restriction is an emerging field, observational studies, case reports and conference abstracts were included in addition to trials. There were no limitations on date or language of publication.
The following databases were searched for relevant articles on the 4th January 2018:
MEDLINE, Embase, AMED (via OVID)
Web of Science
An example of the search strategy used in MEDLINE is shown in Additional file 1 The search terms were updated for each database, in accordance with their specific requirements.
In addition to the database searches, the reference lists of all included articles were hand searched for additional studies alongside relevant systematic reviews. The ClinicalTrials.gov website was searched to identify any trials currently taking place which have not yet been completed or published. As an addition to the original protocol, the ISRCTN database was also searched for planned or ongoing trials. Finally, the first ten pages of google scholar were hand searched for any additional articles.
The results from the database searches were imported into an Endnote library and duplicates were removed during the data screening process.
Selection of studies
Titles and abstracts of the search results were screened independently by two reviewers from a team of five researchers. Any discrepancies were discussed with a third reviewer for resolution, if required. Articles identified for potential inclusion were retrieved in full for further screening against the inclusion/exclusion criteria. Full texts which met the inclusion criteria underwent data extraction.
Data charting forms were used to extract relevant data from the included studies. Charting forms were completed by two reviewers independently, then compared for accuracy. Extracted data included:
Publication Information – Paper title, author details, publication type, study type, year of study
Aims/purpose of the research
Study population – sample size, demographics (age, sex, ethnicity), cancer site and staging, inclusion/exclusion criteria, withdrawals and exclusions
Intervention type and design – Study design, intervention description (including type, timing and duration of dietary restriction)
Key findings – Outcomes reported, and the outcome measures used, adverse events, adherence rates, acceptability and tolerability.
The inclusion flowchart for the review can be seen in Fig. 1.
The database search retrieved 8448 texts for screening and 4 additional manuscripts were identified through hand searches. Title/abstract screening identified 84 texts for full text screening. Fifty were excluded, with reasons recorded in Fig. 1. Thirty-four full texts which pertained to 23 studies in total, were identified for inclusion in the review and underwent data extraction.
Characteristics of included studies
The 23 included studies were published between 2007 and 2017 and included a total sample size of 990 (range 1–596 in the observational studies and range 6–73 in the interventional studies). Four categories of interventions were identified: KDs, fasting, protein restriction and combined interventions. The majority of studies were of KD (n = 10), followed by protein restriction (n = 5), fasting (n = 4), and combined interventions (n = 4). The outcomes reported were varied, ranging from withdrawal rates, treatment side effects (both standard treatment and/or intervention effects) and biological markers. Results were therefore divided into three broad groups of interest: feasibility, tolerability and treatment effects. These results are reported for each intervention category in Tables 1, 2, 3 and 4 described in further detail below. Where adverse events were attributed by authors to the dietary intervention, they have been included under “tolerability”. Where they were reported in relation to their treatment e.g. chemotherapy side effects, they are included under “treatment effects”.
Ten studies of KDs that were conducted alongside treatment for cancer were identified: one randomised controlled trial (RCT) , four single arm trials [22, 23, 25, 26], one non-randomised, parallel design trial  one case control study , one case series  and two retrospective reviews [31, 32]. Four of the studies also included participants who were not on any active treatment at the time of the DR [21, 25, 31, 32]. However, as they reported on outcomes of interest relevant to our research question (e.g., adherence) they were included in the review. The majority of KD studies were in people with brain cancer (n = 6) and the most common form of diet was a 4:1 ratio KD (n = 5). The results are summarised in Table 1.
Feasibility results were varied. Of the six interventional studies, two were terminated early due to poor accrual and adherence [22, 23]. In the remaining four, the proportion of non-completers ranged from 15 to 71%. Adherence was reported in two of the interventional studies and was 40%  in one study and 80%  in the other. However, although both studies used urinary ketones different cut-offs were used to assess adherence.
Weight loss, adverse events and reasons for discontinuation of diet were the main tolerability outcomes reported. In general, weight loss was not a cause for concern on the KDs used, with loss remaining below 10% of initial body weight in the majority of participants. Two trials also broke down weight lost into loss of fat mass and fat free mass. Both found that in spite of weight loss, fat free mass was preserved [21, 29]. Reports of grade 3/4 adverse events were rare.
Intervention effects reported included markers of metabolism such as ketones, glucose and insulin, quality of life and treatment- related adverse events. Of the seven studies that reported on ketones or βeta-hydroxybutyrate specifically (a common ketone), all reported ketosis or an increase in ketones in those on the KD. However, this was not always linked with a corresponding reduction in blood glucose [21, 25, 26, 29]. Champ et al is the exception which found a reduction in blood glucose on KD during radiotherapy, even though participants received steroidal treatment which is known to increase blood glucose . Four studies reported on quality of life [21, 25, 29, 32] with one finding evidence of positive effects , one finding negative effects  and one finding no effect . We were unable to extract results from the fourth study as they were not stratified by diet type .
Five studies of protein restriction were identified, of which four were specifically methionine (MET)-restricted (Table 2). One study was an RCT in people with prostate cancer  while the remaining four were clinical trials with single arm allocation [34,35,36,37] including people with melanoma, glioma and colorectal cancer. One of the single arm trials was a phase 1 trial  which was followed by a phase 2 trial .
MET free diets were delivered as oral powders which participants consumed as drinks. Three of the four MET-free diet studies reported on the mean adherence to the diet which ranged from 72.4 to 92.5% [34, 35, 37]. Feasibility findings were not reported in the RCT of a protein restricted diet .
Tolerability was reported in three trials of the MET restriction. There were no changes in markers of nutritional status (body weight, albumin or pre-albumin) associated with the MET-free diet [34, 35, 37]. In the protein restricted diet trial, the intervention group lost weight, but this was an aim of the trial which recruited overweight participants .
The main outcome of interest within the MET restriction studies was blood MET concentration. All four trials of MET-free diet resulted in a reduction in mean plasma MET concentrations (reductions ranged from 40.7 to 53.1%) which authors reported as successful reduction rates [34,35,36,37]. Outcomes of interest in the total protein restriction trial were cellular effects of the diet, specifically the effect of the diet on molecular mediators in extracellular vesicles. They found that the diet increased the levels of extracellular vesicle-associated leptin receptors and a higher Y/S Insulin receptor substrate-1 ratio in the protein restricted group, indicating improved leptin and insulin sensitivity .
Four studies of fasting were identified, and all were conducted at the time of chemotherapy: One pilot RCT , one dose escalating study , one qualitative study  and a case series report  (Table 3). Each study utilised a different fasting protocol. Self-administered fasts ranged from 48 to 140 h prior to and/or 5–56 h following chemotherapy. Per-protocol fasts ranged from 24 h prior to chemotherapy to 72 h, divided as 48 h prior to chemotherapy and 24 h post-chemotherapy. Each study also included a different clinical population, with varying cancer types.
Feasibility findings were reported in both interventional studies with the pilot RCT reporting a 15% (n = 2) withdrawal rate . Within the dose escalation study, authors reported 67% compliance in the 24 h fast, 83% in the 48 h fast and 57% in the 72 h fast. However, they also note that, although self-reported compliance was high in the 72 h fast, it may have been subject to poorer compliance given that the IGF analysis showed lower than expected reductions in IGF1 at 72 h .
Tolerability of the fast was not discussed in the RCT. However, no grade 3/4 toxicities were reported among participants in the dose-escalating or qualitative studies [40, 43]. Grade 1/2 toxicities are listed in Table 3 and included dizziness, hunger, headaches and weight loss. Among the participants in the qualitative study, 13% (n = 2) reported experiencing adverse events which stopped them following their self-administered fast . In the case series, weight loss was reported to resolve in “most” participants following introduction of normal feeding . Only 1 participant in the dose escalation study did not regain at least 25% of body weight last during the fast between cycles and was unable to continue with the second fast, as per the trial protocol .
The intervention effects of interest within the fasting literature focus on biological markers of metabolism and chemotherapy toxicities. Both interventional studies found a reduction in IGF1 associated with fasting, however the levels were varied depending on the trial and length of the fast. Reductions ranged from 17.3% after 24 h of the 48 h fast  to 33% after the 48 h fast . Despite fasting, neither interventional study found a reduction in glucose, with glucose increasing after 24 h in the RCT  and no changes evident in the dose escalation study . Study authors suggested the use of steroidal treatment among study participants as a potential reason for the lack of glucose reduction during fasting. The two observational studies found evidence of decreased side effects from chemotherapy. This was self-reported in the qualitative study  (side effects that were reduced were not specified) while the case series report found a reduction in fatigue, weakness and gastrointestinal side effects in cycles completed alongside a fast when compared to cycles where cases ate ad-libitum . These findings were similar in the dose escalating study which found a trend for reduced nausea and vomiting in longer fasts  but were not seen in the pilot RCT which found no differences in self-reported AEs between groups .
Four studies of combined interventions were identified and are summarised in Table 4: One RCT  and three case reports [46,47,48]. All combined some form of ketogenic or low carbohydrate diet with additional interventional aspects such as increased physical activity in the RCT , or additional dietary changes [46,47,48]. As the diets were delivered in combination with other components and the majority are based on single patient case reports, interpretation is limited. However, the RCT reported a high retention rate of 81% and found that the main side effect associated with the low carbohydrate and increased physical activity intervention was mild headaches .
The clinicaltrials.gov and ISRCTN databases were searched on 10th December 2018 for studies that were registered as ongoing or planned. This search identified: 13 trials of KD, one trial of a KD combined with short term fasting, one trial of short term fasting, five trials of fasting-mimicking diets and two trials of intermittent fasting. These are summarised in Table 5. This search indicates that the KD continues to be the most researched form of restriction (n = 13) and the majority of these studies are in people with brain cancer (n = 8). Although there are an increasing number of KD RCTs identified (n = 5), three specifically identify as pilot/feasibility studies, and all have small target sample sizes (range = 12–60). An increased interest in other forms of fasting such as intermittent fasting (n = 2) and fasting-mimicking diets (n = 5) is also evident. Fasting RCT target sample sizes range from 30 to 250.
Few studies have been published on DR during treatment for cancer to date, particularly when the data are stratified by restriction type. More studies are currently in progress and due to complete recruitment within the next 3 years, which identifies DR as a research area of growing interest. However, most ongoing trials are early stage studies with small sample sizes. These may allow us to further understand the feasibility of conducting such studies but will not enable conclusions to be drawn about the efficacy of these interventions. Large studies with long-term outcomes are needed to definitively address these questions.
Our findings show that the most commonly studied form of dietary restriction is the KD. As with the previous review of KD in adults with cancer not specifically receiving treatment for cancer, we found the 4:1 diet to be the most common form being used in conjunction with treatment . The previous review concluded that adherence rates were low, and our review confirms the potential issues surrounding adherence when using KD alongside treatment for cancer. Adherence results were varied, with different definitions of adherence and tolerability used, making comparisons of adherence to the different forms of the KD difficult. This, in combination with the early termination of two of the KD trials, suggest that further research into improving acceptability of KDs may be warranted. For example, there could be the potential for improved adherence and retention in KD studies with lower ratios of fat:carbohydrate than the 4:1 diet whilst still achieving favourable metabolic changes . Furthermore, as most studies of KD reported few issues with tolerability and weight loss, it is possible that there could be issues with palatability or sustainable behavioural change.
The results of protein restriction research suggested that MET-free diets were adhered to well with limited tolerability issues. However, the diets were provided over a short amount of time as oral solutions. It is less clear how well general protein restriction as part of a low protein meal-based diet is adhered to, as only a single trial of overall protein restriction has been conducted, which did not report feasibility outcomes.
Very few studies of fasting have been conducted. Overall, the studies to date have found that participants are able to follow short-term fasts, although length of interventions varied, and it is unclear whether longer fasts have lower adherence. As with the other dietary restriction methods, adverse events related to fasting did not appear to affect adherence in the majority of studies, with the exception of the qualitative study . This may be because participants in that study were self-administering the fast and not receiving clinical support. As with the research on KDs, fasting appears to result in a reduction in IGFs. However, it remains unclear whether it also results in a decrease in blood glucose. This may be due to steroidal treatment received alongside chemotherapy, which is known to increase blood glucose levels. One interventional and two observational studies found some evidence of reduced toxicities in fasted participants, however the evidence is limited by the small number of trials and small sample sizes included.
Larger, adequately powered RCTs will be required in order to study the efficacy of each DR intervention type to reduce treatment side effects or improve outcomes. Within KD research, further exploration of issues associated with adherence is warranted if larger trials are to test this intervention. There is a current lack of in-depth qualitative work conducted in this area, which may help in exploring the reasons for non-compliance in trials, especially if tolerability is high.
While research into MET-free diets suggest that trials of this intervention are feasible, definitive RCTs with larger sample sizes are required to ascertain whether these diets result in reduced treatment side effects or improved outcomes. Further research into adherence to and tolerability of general protein restricted diets is required in order to understand the feasibility of conducting this form of intervention alongside treatment of cancer. It is also not clear whether this diet could be introduced to people with normal weight without resulting in significant weight loss, as the only trial to date was in people who were overweight.
Conflicting findings regarding blood glucose levels suggest further research into the effect of dietary restriction on this marker is required. Attention should also be paid to the use of steroidal treatment alongside chemotherapy, to investigate whether increased blood glucose seen with these drugs inhibits the potentially protective effect of dietary restriction. In a current study of fasting-mimicking diets the investigators have chosen to omit dexamethasone treatment . However, on a pragmatic level, it would also be of interest to explore whether IGF reduction alone is able to induce metabolic changes that would be sufficient to achieve a reduction in toxicity, even in the presence of dexamethasone. Particularly as two observational and one interventional study found some evidence for reduced side effects when chemotherapy was provided as standard. Reporting on the type of weight-loss resulting from the fast would also be of interest, to ascertain whether fat is lost while lean muscle mass is retained, as has been the case in KDs.
Strengths and limitations
While some aspects of dietary restriction have been reviewed previously [16, 17], this scoping review employed a systematic search of the literature on the different forms of dietary restriction during treatment for cancer, to collate the research to date. Although every effort was made in the search to identify all relevant texts, it is possible that some studies of DR during treatment for cancer have been missed.
In order to acknowledge the emerging nature of DR research, a scoping review process was followed, which included data from observational and single-arm studies. This allowed us to consider the breadth of previous research in an emerging field, helping to inform future studies. However, this also means that the quality of studies has not been assessed against the standards commonly used in systematic reviews of RCTs. This approach has allowed us to summarise the emerging research on DR in cancer treatment and highlights some issues that should be considered when designing further studies in this area.
DR regimes are a potential tool to help reduce the toxicities associated with cancer treatment. However, the limited number of studies to date have had small samples and have not been designed to specifically test the efficacy of these interventions. DR is, however, a growing research area with further trials being conducted. Definitive RCTs are required to assess the efficacy of DR during cancer treatment on reducing treatment related toxicities or improving treatment outcomes. This scoping review has highlighted the potential problem of adherence issues and as such suggests further research into improving dietary compliance is conducted before larger efficacy trials are conducted. Further research into the effect of DR interventions on cellular metabolism when used in combination with treatment is also warranted.
Availability of data and materials
Data is currently only accessible to members of the study research team but may also be made available on reasonable request by contacting the corresponding author.
Biomedical Research Centre
Insulin-like Growth Factor
International Standard Randomised Controlled Trial Number registry
National Institute for Health Research
Randomised controlled trial
Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci. 2008;105(24):8215–20.
Brandhorst S, Harputlugil E, Mitchell JR, Longo VD. Protective effects of short-term dietary restriction in surgical stress and chemotherapy. Ageing Res Rev. 2017;39(Supplement C):68–77.
Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene. 2011;30(30):3305–16.
Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci. 2010;31(2):89–98.
Seyfried TN, Yu G, Maroon JC, D’Agostino DP. Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. Nutr Metab. 2017;14(1):19.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic Requirements of cell proliferation. Science (New York, NY). 2009;324(5930):1029–33.
Doerstling SS, O’Flanagan CH, Hursting SD. Obesity and cancer metabolism: a perspective on interacting tumor–intrinsic and extrinsic factors. Front Oncol. 2017;7:216.
Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211–8.
O’Flanagan CH, Smith LA, McDonell SB, Hursting SD. When less may be more: calorie restriction and response to cancer therapy. BMC Med. 2017;15(1):106.
Woolf EC, Syed N, Scheck AC. Tumor Metabolism, the ketogenic diet and β-hydroxybutyrate: novel approaches to adjuvant brain tumor therapy. Frontiers Mol Neurosci. 2016;9(122). https://doi.org/10.3389/fnmol.2016.00122.
Brandhorst S, Choi In Y, Wei M, Cheng Chia W, Sedrakyan S, Navarrete G, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metabolism. 2015;22(1):86–99.
Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy. Pediatrics. 2000;105(4):e46-e.
Rizza W, Veronese N, Fontana L. What are the roles of calorie restriction and diet quality in promoting healthy longevity? ageing research reviews. Ageing Res Rev. 2014;13(Supplement C):38–45.
Jeon H, Kim JH, Lee E, Jang YJ, Son JE, Kwon JY, et al. Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo. Oncotarget. 2016;7(41):67223–34.
Sun L, Li Y-J, Yang X, Gao L, Yi C. Effect of fasting therapy in chemotherapy-protection and tumorsuppression: a systematic review. Transl Cancer Res. 2017;6(2):354–65.
Sremanakova J, Sowerbutts AM, Burden S. A systematic review of the use of ketogenic diets in adult patients with cancer. Clin Nutr. 2018;37:S191.
Colquhoun HL, Levac D, O'Brien KK, Straus S, Tricco AC, Perrier L, et al. Scoping reviews: time for clarity in definition, methods, and reporting. J Clin Epidemiol. 2014;67(12):1291–4.
Shingler ES, Perry R, Perks CM, Herbert G, Ness A, Atkinson C. Dietary restriction during the treatment of cancer: a scoping review protocol of restriction methods and their acceptability 2017. Available from: https://research-information.bristol.ac.uk/en/projects/dietary-restriction-during-the-treatment-of-cancer-a-scoping-review-protocol-of-restriction-methods-and-their-acceptability(c1026608-cdf4-4dc1-a4ba-d6b6ba15e7c3).html. Accessed 5 Aug 2019.
The Joanna Briggs Institute. The Joanna Briggs Institute Reviewers’ Manual 2015 Methodology for JBI Scoping Reviews 2015.
Cohen C, Londono-Joshi A, Gower B, Alvarez R, Leath C, Turner T, et al. A Ketogenic diet improves metabolic health and decreases angiogenesis in women with recurrent ovarian cancer. Int J Gynecol Cancer. 2016;26:752.
Anderson CM, Loth E, Opat E, Bodeker K, Ahmann L, Parkhurst J, et al. A Phase 1 Trial of Ketogenic Diet With Concurrent Chemoradiation (CRT) in Head and Neck Squamous Cell Carcinoma (HNSCC). Int J Radiat Oncol Biol Phys. 2016;94(4):898.
Dardis C, Renda L, Honea N, Smith K, Nakaji P, Ashby LS, et al. Therapeutic ketogenic diet (KD) with radiation and chemotherapy for newly diagnosed glioblastoma-preliminary results from NCT02046187. Neuro-Oncol. 2017;19(Supplement 6):vi4.
Rieger, J., et al., Erratum: ERGO: A pilot study of ketogenic diet in recurrent glioblastoma (International Journal of Oncology (2014) 44 (1843-1852) DOI: 10.3892/ijo.2014.2382). International Journal of Oncology, 2014. 45(6): p. 2605.
Rieger J, Baehr O, Hattingen E, Maurer G, Coy J, Weller M, et al. The ERGO trial: A pilot study of a ketogenic diet in patients with recurrent glioblastoma. J Clin Oncol Conf. 2010;28(15 SUPPL. 1).
Zahra A, Fath MA, Opat E, Mapuskar KA, Bhatia SK, Ma DC, et al. Consuming a ketogenic diet while receiving radiation and chemotherapy for locally advanced lung cancer and pancreatic cancer: the university of Iowa experience of two phase 1 clinical trials. Radiat Res. 2017;187(6):743–54.
Artzi M, Liberman G, Vaisman N, Bokstein F, Vitinshtein F, Aizenstein O, et al. Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: H-1-MRS study. J Neuro-Oncol. 2017;132(2):267–75.
Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neuro-Oncol. 2014;117(1):125–31.
Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: I. Initial clinical experience with six prospectively studied patients. BMC Res Notes. 2016;9:143.
Attar, H., et al., The modified atkins diet in recurrent glioma: A retrospective review. Neuro-Oncology, 2015. 5): p. v7.
Attar H, Rolfe S, Marsey M, Rogers L. Results of the modified atkins diet in patients with recurrent glioma: Retrospective review. Neurology Conference: 68th American Academy of Neurology Annual Meeting, AAN. 2016;86(16 SUPPL. 1).
Randazzo DM, McSherry F, Herndon IJE, Affronti ML, Lipp ES, Flahiff C, et al. Diet and health-related quality of life (HRQoL) in the primary brain tumor population. Neuro-Oncology. 2015;5:v192.
Eitan E, Tosti V, Suire CN, Cava E, Berkowitz S, Bertozzi B, et al. In a randomized trial in prostate cancer patients, dietary protein restriction modifies markers of leptin and insulin signaling in plasma extracellular vesicles. Aging Cell. 2017;16(6):1430–3.
Durando X, Thivat E, Farges M, Cellarier E, D'Incan M, Demidem A, et al. Optimal methionine-free diet duration for nitrourea treatment: a phase I clinical trial. Nutr Cancer. 2008;60(1):23–30.
Durando X, Farges MC, Buc E, Abrial C, Petorin-Lesens C, Gillet B, et al. Dietary methionine restriction with FOLFOX regimen as first line therapy of metastatic colorectal Cancer: a feasibility study. Oncology. 2010;78(3–4):205–9.
Thivat E, Durando X, Demidem A, Farges MC, Rapp M, Cellarier E, et al. A methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer. Anticancer Res. 2007;27(4C):2779–83.
Thivat E, Farges MC, Bacin F, D'Incan M, Mouret-Reynier MA, Cellarier E, et al. Phase II trial of the Association of a Methionine-free Diet with Cystemustine therapy in melanoma and glioma. Anticancer Res. 2009;29(12):5235–40.
de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer. 2015;15(1):652.
de Groot S, Vreeswijk MPG, Smit V, Heijns JB, Imholz ALT, Kessels LW, et al. DIRECT: a phase II/III randomized trial with dietary restriction as an adjunct to neoadjuvant chemotherapy for HER2-negative breast cancer. Cancer Res. 2013;73.
Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, et al. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016;16(1):360.
Mas S, Le Bonniec A, Cousson-Gelie F. Why do patients fast during chemo? Patients' experience of and motivation for fasting during treatment. Psycho-Oncology. 2017;26(Supplement 3):88.
Safdie, F.M., et al., Fasting and cancer treatment: A case series. Cancer Research, 2010. 70.
Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, et al. Fasting and cancer treatment in humans: a case series report. Aging (Albany NY). 2009;1(12):988–1007.
Freedland S, Aronson W, Howard L, Smith J, Smith M, Stout J, et al. A prospective randomized trial of dietary carbohydrate restriction for men initiating androgen deprivation therapy: Carbohydrate and prostate study I (CAPS1). J Urol. 2016;1:e29–30.
Branca, J.J.V., S. Pacini, and M. Ruggiero, Effects of Pre-surgical Vitamin D Supplementation and Ketogenic Diet in a Patient with Recurrent Breast Cancer. Anticancer Research, 2015. 35(10): p. 5525–5532.
Reinwald H. Natural cancer therapy based on a ketogenic diet with master amino acid pattern and vitamin D-binding protein-based immunotherapy. Breast Cancer Manag. 2015;4(5):245–9.
Iyikesici MS, Slocum AK, Slocum A, Berkarda FB, Kalamian M, Seyfried TN. Efficacy of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy for stage IV triple-negative breast Cancer. Cureus. 2017;9(7):e1445.
Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab. 2010;7. https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/1743-7075-7-33.
This study was funded by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre (BRC) Nutrition Theme, based at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this manuscript are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Shingler, E., Perry, R., Mitchell, A. et al. Dietary restriction during the treatment of cancer: results of a systematic scoping review. BMC Cancer 19, 811 (2019) doi:10.1186/s12885-019-5931-7